Resources

In this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of studies such as the head-to-head trial of two long-acting basal insulins.

In part 1 of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the various trials of interest presented at the conference, such as the latest regarding the study of two basal insulins.

In part 2 of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the products in the works at Sanofi.

In part 3, the conclusion of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the focus on the impact of certain medications on specific populations.

New technologies have the potential to revolutionize diabetes care. But what are the advantages and disadvantages of insulin pumps, vs. daily injections? How widely will they be adopted, by patients with type 2 diabetes as well as type 1? What factors will make a difference for adoption – convenience, accuracy, costs? In November, we asked you to help us examine the future of insulin delivery and find the answers to these questions. Now we’re sharing all the results with you, so that you can see for yourself how your fellow members of the diabetes community plan on using CGMs, now and in the future.

Even though most diabetes drugs can help in managing blood sugar levels, they can also be detrimental to the heart.

Study findings warrant cautious consideration and discussions about risk vs benefit when considering therapy.

Study compares enhanced patient care experience with standard shared medical appointments to determine if a significant benefit will result.

John S. is a 63-year-old Caucasian man with significant abdominal obesity, type 2 diabetes, hypertension, and dyslipidemia as well. On the basis of an exercise stress test, John was recently diagnosed with silent ischemia. John’s current medications include metformin, a DPP-4 inhibitor, an ACE inhibitor/HCTZ agent, a calcium channel blocker, a high-dose statin, and ezetimibe. John’s relevant physical exam and laboratory findings are as follows:

BMI 34.8 kg/m2
Blood pressure 140/86 mm Hg
HbA1C 7.2%
Total cholesterol 150 mg/dL
LDL-C 79 mg/dL
HDL-C 42 mg/dL
Triglycerides 145 mg/dL
non-HDL-C 118 mg/dL
eGFR 65 mL/min/1.73 m2
ACR 100 mg albumin/g creatinine

You explain John’s options for antihyperglycemic therapy. Which of the following answers most accurately describes the extraglycemic benefits of the different options?

A. The GLP-1 receptor agonists may improve endothelial function and reduce infarct size and the SGLT2 inhibitors are likely to improve arterial blood flow.
B. The DPP-4 inhibitors are not safe for people with cardiovascular disease, while the proven cardiovascular benefits of GLP-1 receptor agonists are consistent across the class.
C. DPP-4 inhibitors and SGLT2 inhibitors both reduce blood pressure, which accounts for their similar effects on heart failure.
D. The cardiovascular benefits of both the GLP-1 receptor agonists and SGLT2 inhibitors derive mainly from their effects on weight.

Follow the link for the answer.

Which insulin pump do you prefer for most of your patients? Medtronic, Tandem, or Omnipod? Follow the link to share your opinion.